| Literature DB >> 27158780 |
Joshua D Campbell1,2, Anton Alexandrov3,4, Jaegil Kim1, Jeremiah Wala1,2, Alice H Berger1,2, Chandra Sekhar Pedamallu1,2, Sachet A Shukla1,2, Guangwu Guo1,2, Angela N Brooks1,2, Bradley A Murray1,2, Marcin Imielinski1,2,5, Xin Hu6, Shiyun Ling6, Rehan Akbani6, Mara Rosenberg1, Carrie Cibulskis1, Aruna Ramachandran1,2, Eric A Collisson7, David J Kwiatkowski1,8, Michael S Lawrence1, John N Weinstein6, Roel G W Verhaak6, Catherine J Wu1,2, Peter S Hammerman1,2, Andrew D Cherniack1,2, Gad Getz1,9, Maxim N Artyomov3, Robert Schreiber3, Ramaswamy Govindan10, Matthew Meyerson1,2,11.
Abstract
To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers of lung carcinogenesis, we examined the exome sequences and copy number profiles of 660 lung ADC and 484 lung SqCC tumor-normal pairs. Recurrent alterations in lung SqCCs were more similar to those of other squamous carcinomas than to alterations in lung ADCs. New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types. New amplification peaks encompassed MIR21 in lung ADC, MIR205 in lung SqCC, and MAPK1 in both. Lung ADCs lacking receptor tyrosine kinase-Ras-Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and ARHGAP35. Regarding neoantigens, 47% of the lung ADC and 53% of the lung SqCC tumors had at least five predicted neoepitopes. Although targeted therapies for lung ADC and SqCC are largely distinct, immunotherapies may aid in treatment for both subtypes.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27158780 PMCID： PMC4884143 DOI： 10.1038/ng.3564
Source DB: PubMed Journal: Nat Genet ISSN： 1061-4036 Impact factor: 38.330